Magnetic Resonance Imaging Based Risk Stratification for Defibrillator Implantation in Heart Failure Patients Requiring Cardiac Resynchronisation Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVelammal Medical College Hospital and Research Institute

About this trial

This randomized study aimed to compare the efficacy of LBBP without defibrillator vs biventricular pacing with defibrillator (BiV-ICD/CRT-D) in patients with LB-NICM and left ventricular ejection fraction (LVEF) ≤35% risk categorized by CMR imaging.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with age ≥18 years

Typical left bundle branch block as defined by Strauss criteria with LVEF ≤35%

Heart failure symptoms despite guideline directed medical therapy (GDMT)

Disqualifiers

Patients with angiographic evidence of significant coronary artery disease requiring revascularisation. In patients with significant CAD, LVEF will be re-assessed 3 months after revascularisation to decide about CRT

Patients with associated uncorrected congenital or valvular heart disease

Expected life-expectance of <12 months due to associated comorbidities

Patients with contrast allergy

Trial design

Design model

Parallel

Treatments tested in this trial

  • left bundle branch pacing

    Device

    Capture of left bundle branch fibers by positioning the lead deep inside the proximal inter ventricular septum. Atrial lead will positioned in the right atrium

  • Biventricular pacing with defibrillator

    Device

    Biventricular pacing with right ventricular ICD lead and coronary sinus lead. Atrial lead will be positioned in the right atrium

Treatment groups

114 Participants
are divided into 2 treatment groups
Group A: LBBP without defibrillator:Experimental treatment 1 intervention
Group B: BiV-ICDActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of participants with the following treatment related events in each arm

1. Composite of occurrence 1. death, 2. HFH, or 3. sustained VT at 12 months 2. Echocardiographic response (ER) defined as absolute increase in LVEF by \>15% at 12 months

Time frame
12 months

Secondary outcomes

1

Number of participants with the following treatment related events in each arm

1. Echocardiographic hyper-response (EHR) defined as normalisation of LVEF (≥50%) at 6 and 12 months 2. Need for ICD upgrade (persistent LVEF \<35% or sustained VT/VF) at 12 months

Time frame
6 and 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.